Nocturnal acid breakthrough: Clinical significance and management

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue SUPPL. 5, 2006, Pages

  Ang, Tiing Leong ^a   Fock, Kwong Ming ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Acid breakthrough; Proton pump inhibitors

Indexed keywords

ANTIHISTAMINIC AGENT; BENATOPRAZOLE; ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

CLINICAL TRIAL; DRUG TOLERABILITY; ESOPHAGUS; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; HALF LIFE TIME; HELICOBACTER PYLORI; HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW; STOMACH PH;

EID: 33750913343     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04717.x     Document Type: Review

References (26)

1. Fock KM, Talley N, Hunt R et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J. Gastroenterol. Hepatol. 2004; 19: 357-67.
2. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am. J. Gastroenterol. 1998; 93: 763-7.
3. Tutuian R, Castell DO. Nocturnal acid breakthrough - approach to management. Medgenmed 2004; 6: 11.
4. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment. Pharmacol. Ther. 1998; 12: 1235-40.
5. Gillen D, Wirz AA, Neithercut WD, Ardill JES, McColl KEL. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999; 44: 468-75.
6. Katsube T, Adachi K, Kawamura A et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment. Pharmacol. Ther. 2000; 14: 1049-56.
7. Martinek J, Pantoflickova D, Hucl T et al. Absence of nocturnal acid breakthrough in Helicobacter pylori -positive subjects treated with twice daily omeprazole. Eur. J. Gastroenterol. Hepatol. 2004; 16: 445-50.
8. Katz PO, Anderson C, Khoury R, Castell DO. Gastroesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment. Pharmacol. Ther. 1998; 12: 1231-4.
9. Fouad YM, Katz PO, Castell DO. Esophageal motility defects associated with nocturnal gastroesophageal reflux on proton pump inhibitors. Aliment. Pharmacol. Ther. 1999; 13: 1467-71.
10. Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitors. Aliment. Pharmacol. Ther. 2002; 16: 1309-16.
11. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am. J. Gastroenterol. 2003; 98: 545-50.
12. Pehlivanov ND, Olyaee M, Sarosiek I, McCalum RW. Comparison of morning and evening administration of rabeprazole for gastroesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross over study. Aliment. Pharmacol. Ther. 2003; 18: 883-90.
13. Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment. Pharmacol. Ther. 2004; 19: 1105-10.
14. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 1999; 13 (Suppl 3): 27-36.
15. Wang H, Nie YQ, Dai SJ, She QZ, Li YY. The effect of proton pump inhibitor on intragastric acidity and its relationship to S-mephenytoin hydroxylase genetic polymorphism. Zhonghua Nei Ke Za Zhi 2003; 42: 777-80.
16. Shimatani T, Inoue M, Kuroiwa T, Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment. Pharmacol. Ther. 2004; 19: 113-22.
17. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
18. Xue S, Katz PO, Banerjee P, Tutian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric control in GERD patients on proton pump inhibitors. Aliment. Pharmacol. Ther. 2001; 15: 1351-6.
19. Tõrûner M, Bektas M, Cetinkaya H, Soykan I, Õzden A. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study. Turk. J. Gastroenterol. 2004; 15: 225-8.
20. Sugimoto M, Furuta T, Shirai N et al. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relationship to cytochrome P450 2C10 genotypes. Clin. Pharmacol. Ther. 2005; 77: 302-11.
21. Khoury RM, Katz PO, Hammod R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment. Pharmacol. Ther. 1999; 13: 675-8.
22. Orr WC, Harnish MJ. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal esophageal and gastric acidity. Aliment. Pharmacol. Ther. 2003; 17: 1553-8.
23. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
24. Adachi K, Komazawa Y, Fujishiro H et al. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori negative subjects: effects of different regimens. J. Gastroenterol. 2003; 38: 830-5.
25. Galmiche JP, Bruley Des Varannes S, Ducrotte P et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment. Pharmacol. Ther. 2004; 19: 655-62.
26. Hunt RH, Armstrong D, James C et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am. J. Gastroenterol. 2005; 100: 1949-56.